IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation

  1. Li Pan
  2. Madeleine E Lemieux
  3. Tom Thomas
  4. Julia M Rogers
  5. Colin H Lipper
  6. Winston Lee
  7. Carl Johnson
  8. Lynette M Sholl
  9. Andrew P South
  10. Jarrod A Marto
  11. Guillaume O Adelmant
  12. Stephen C Blacklow
  13. Jon C Aster  Is a corresponding author
  1. Brigham and Women's Hospital, United States
  2. Bioinfo, Canada
  3. Harvard Medical School, United States
  4. Thomas Jefferson University, United States
  5. Dana-Farber Cancer Institute, United States
  6. Dana Farber Cancer Institute, United States
  7. Harvard, United States

Abstract

Notch signaling regulates squamous cell proliferation and differentiation and is frequently disrupted in squamous cell carcinomas, in which Notch is tumor suppressive. Here, we show that conditional activation of Notch in squamous cells activates a context-specific gene expression program through lineage-specific regulatory elements. Among direct Notch target genes are multiple DNA damage response genes, including IER5, which we show is required for Notch-induced differentiation of squamous carcinoma cells and TERT-immortalized keratinocytes. IER5 is epistatic to PPP2R2A, a gene that encodes the PP2A B55a subunit, which we show interacts with IER5 in cells and in purified systems. Thus, Notch and DNA-damage response pathways converge in squamous cells on common genes that promote differentiation, which may serve to eliminate damaged cells from the proliferative pool. We further propose that crosstalk involving Notch and PP2A enables tuning and integration of Notch signaling with other pathways that regulate squamous differentiation.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE156488 and GSE156624

The following data sets were generated

Article and author information

Author details

  1. Li Pan

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  2. Madeleine E Lemieux

    Bioinfo, Ontario, Canada
    Competing interests
    No competing interests declared.
  3. Tom Thomas

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  4. Julia M Rogers

    Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Colin H Lipper

    Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  6. Winston Lee

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  7. Carl Johnson

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  8. Lynette M Sholl

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  9. Andrew P South

    Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, United States
    Competing interests
    No competing interests declared.
  10. Jarrod A Marto

    The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  11. Guillaume O Adelmant

    Oncologic Pathology, Dana Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  12. Stephen C Blacklow

    Department of Biological Chemistry and Molecular Pharmacology, Harvard, Boston, United States
    Competing interests
    Stephen C Blacklow, SCB is on the SAB for Erasca, Inc., receives sponsored research funding from Novartis and Erasca, Inc, and is a consultant for IFM therapeutics and Ayala Pharmaceuticals..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6904-1981
  13. Jon C Aster

    Department of Pathology, Brigham and Women's Hospital, Boston, United States
    For correspondence
    jaster@rics.bwh.harvard.edu
    Competing interests
    Jon C Aster, JCA is a consultant for Ayala Pharmaceuticals and for Cellestia, Inc. There is no conflict of interest with the work described in this manuscript..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1957-9070

Funding

Ludwig Institute for Cancer Research (None)

  • Jon C Aster

National Institutes of Health (R35 CA220340)

  • Stephen C Blacklow

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Pan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,297
    views
  • 236
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Li Pan
  2. Madeleine E Lemieux
  3. Tom Thomas
  4. Julia M Rogers
  5. Colin H Lipper
  6. Winston Lee
  7. Carl Johnson
  8. Lynette M Sholl
  9. Andrew P South
  10. Jarrod A Marto
  11. Guillaume O Adelmant
  12. Stephen C Blacklow
  13. Jon C Aster
(2020)
IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation
eLife 9:e58081.
https://doi.org/10.7554/eLife.58081

Share this article

https://doi.org/10.7554/eLife.58081

Further reading

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ashley L Cook, Surojit Sur ... Nicolas Wyhs
    Research Article

    Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.